Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
The Company has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.
Actavis is the world's third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.
Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world’s largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.
Actavis Specialty Brands is the Company’s global branded specialty pharmaceutical business, principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories. Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories, and currently has a portfolio of five biosimilar products in development.
Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually. Actavis Global Operations also includes Anda, Inc., a U.S. generic pharmaceutical product distributor.
View Actavis’ Company Profile (pdf, 2.9MB)